Day 2 :
Keynote Forum
I B Vijayalakshmi
Bangalore Medical College and Research Institute, India
Keynote: Novel method of patent ductus arteriosus closure in preterm neonates with nano-ibuprofen eluting balloon
Time : 09:00-09:40
Biography:
I B Vijayalakshmi is the first to start Pediatric Cardiology in South India. She has won 34 gold medals, My Nightmare Case award twice at PICS. She has 86 publications and has edited four cardiology books.
Abstract:
Background: Patent ductus arteriosus (PDA) occurs frequently in preterm babies (14%). Treating PDA with oral ibuprofen is common. However large PDAs with pump failure, refractive to medical therapy undergo either surgical ligation or device closure, which carry significant inherent morbidity.Aim: Aim of this study is to evaluate, effect of drug eluting balloons coated with inorganic nanoparticles of ibuprofen in rabbits, initially and then in preterm neonates.Methods: In this proposed prospective study, PDA in rabbits is treatment with drug eluting 3X10 mm coronary balloon coated with inorganic nanoparticles of Ibuprofen. Through the femoral vein 4F catheter is passed via the inferior vena cava, right atrium, right ventricle and pulmonary artery. Then PDA is crossed with a Terumo guide wire under fluoroscopy, the drug eluting balloon is positioned in PDA. The balloon is inflated for 3 min to release the ibuprofen nano particles. Slowly, the balloon is deflated over 3 min to demonstrate duct closure by echocardiography. The balloon and guide wire are removed. Serial echocardiograms are performed to assess the efficacy after 6, 12, 24 and 48 hours. The primary outcomes are noted, along with survival without major neonatal morbidity. Finally, histo-pathological studies of ductal tissue are done.Results: The proportion of PDA closure with drug eluting balloon versus oral ibuprofen will be interrogated. The difference between two groups and the P value will be calculated. (using: SPSS- Prism t test).Conclusions: This novel study of balloon coated with inorganic nanoparticles of Ibuprofen in rabbits could be path breaking.
Keynote Forum
Aharon Gedanken
Bar-Ilan University, Isarel
Keynote: Title: Making the hospital a safer place by the sonochemical coating of the textiles with antibacterial nanoparticles
Time : 09:40-10:20
Biography:
Emeritus Prof. Aharon Gedanken obtained his M. Sc. from Bar-Ilan University, and his Ph. D. degree from Tel Aviv University, Israel. After his postdoctoral research at USC in Los Angeles, he returned to Bar-Ilan in 1975 as a senior faculty. He was a visiting scientist at AT&T Bell Laboratories in 1980-8l, 1984, and 1987-88, and at NIDDK, NIH in the summers of 1989, 1990 and 1991. In 1994 he switched his research interest from Spectroscopy to Nanotechnology. His special synthetic methods of nanomaterials include: Sonochemistry, Microwave Superheating, Sonoelectrochemistry, and Reactions under Autogenic Pressure at Elevated Temperatures (RAPET). Since 2004 he is mostly focused on the applications of nanomaterials. Gedanken has published 762 per-reviewed manuscripts in international journals, and has applied for 38 Patents. His H-Index is 80. Gedanken has served as the Department chairman as well as the Dean of the Faculty of Exact Sciences at Bar-Ilan University. He is on the editorial boards of 7 international journals. He leads a group of 16 research people. He was a partner in five EC FP7 projects one of them, SONO, was coordinated by him. This project was announced by the EC as a “Success Story”. He was awarded the prize of the Israel Vacuum Society and the Israel Chemical Society for excellence in Research
Abstract:
Sonochemistry is an excellent technique to coat nanomaterials on various substrates, imparting new properties to the substrates. After a short demonstration of coating NPs on ceramics and stainless steel, I'll present the coating of textiles such as polyester, cotton, and nylon. In all cases a homogeneous coating of NPs was achieved. Silver is known for generations as antibacterial, and indeed the Ag NPs have killed the gram-negative E. Coli (strain 1313) as well as the gram-positive Staphylococus aureus (strain 195) bacteria very efficiently. Lately, the FDA shows less enthusiasm towards nanoAg, as a result, we have moved to NPs of ZnO, and CuO as antibacterial agents. They were coated on the above-mentioned fabrics and showed excellent antibacterial properties. The coated textiles were examined for the changes in the mechanical strength of the fabric. A special attention was dedicated to the question whether the NPs are leaching off the fabric when washed repeatedly. The coated ZnO NPs on cotton underwent 65 washing cycles at 92 0 C in water in a Hospital washing machine, no NPs were found in the washing solution and the antibacterial behavior was maintained. Recently, an experiment was conducted at PIGOROV Hospital in Sofia, Bulgaria in which one operation room was equipped with antibacterial textiles, namely, bed sheets, pajamas, pillow covers, and bed covers. 22 Patients in this operation room were probed for bacterial infections. Their infection level was compared with 17 control patient that were using regular textiles. The results are demonstrating that a lower infection level is observed for those patient exposed to the antibacterial textiles. Lately, we have synthesized NPs of a new material, Cu0.89Zn0.11O that kills bacteria 10,000 times better than ZnO or CuO. The mechanism of the killing was studied and will be presented.Coating of Catheters with the above mentioned NPs were performed and the coated catheters were inserted in rabbits. Results showed that the urine of the rabbits was not contaminated with bacteria and the growth of biofilm on the Catheters is avoided.
Keynote Forum
Stoyan Sarg Sargoytchev
World Institute for Scientific Exploration, USA
Keynote: Using the BSM-SG atomic models and their physical properties for modeling and analysis in sub-nano metric scale
Time : 10:20-11:00
Biography:
Stoyan Sarg Sargoytchev has completed his degree of Masters of Electrical Engineering from Technical University in Sofia and PhD in Physics from Bulgarian Academy of Sciences. Currently, he is with the World Institute for Scientific Exploration. He has published more than 70 scientific papers in reputed journals and he is an author of a theoretical monograph BSM-SG.
Abstract:
The BSM-SG atomic models are one of major derivatives of the basic structures of matter super-gravitation unified theory, according to which the near field of atomic nuclei exhibits a space micro-curvature. The re-examination of scattering experiments from this point of view reveals a complex three-dimensional nuclear structure. The effect of space micro-curvature hides the real dimensions of the nuclei, which are with a much larger overall size. Therefore, the coulomb barrier is not as strong as considered by the quantum mechanical models based on the Bohr model of hydrogen. This explains why some nuclear reactions are possible at accessible temperatures. The arrangement of the protons and neutrons in the nuclear structure according to the BSM-SG models matches perfectly the pattern of the periodic table. The nuclear spin also carries a signature of the nuclear configuration and obtains a classical explanation. The reveled structures of BSM-SG atoms and elementary particles exhibit all known quantum mechanical properties while operating with real dimensions. This opens a new opportunity for graphical modeling and analysis in different fields of nanotechnology. The BSM-SG atomic nuclei possess clearly identifiable oxidation numbers and angular directions of the possible chemical bonds. This permits 3D graphical modeling in structural chemistry and biomolecules.
Keynote Forum
Shaker A Mousa
Albany College of Pharmacy and Health Sciences, USA
Keynote: Advanced drug delivery: Nano-targeted delivery for therapeutic and imaging
Time : 11:20-12:00
Biography:
Shaker A Mousa has completed his PhD from Ohio State University, College of Medicine in Columbus and Postdoctoral Fellowship from University of Kentucky in Lexington KY. He also has completed his MBA from Widener University, Chester, PA. He is currently an endowed tenure Professor and Executive Vice-President and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research at ACPHS. He holds over 350 US and International Patents discovering novel anti-angiogenesis strategies, anti-thrombotics, anti-integrins, anti-cancer and non-invasive diagnostic imaging approaches employing various Nanotechnology platforms. He has published more than 1,000 journal articles, book chapters, published patents and books as editor and author. He is a member of several NIH study sections and the Editorial board of several high impact Journals. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular and cardiovascular diseases.
Abstract:
Targeted delivery of drug incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands can not only enhance the efficacy of the anticancer drug but also reduce the unwanted toxicity of the drug. Additionally, multifunctional characteristics of the nano-carrier system would allow for simultaneous imaging of tumor mass, targeted drug delivery and monitoring. A summary of recent progress in nanotechnology as it relates specifically to nanoparticles and anticancer drug delivery will be reviewed. Nano nutraceuticals using combination of various natural products provide a great potential in cancer management. Additionally, various Nano-medicine approaches for the detection and treatment of various types of clots organ specific delivery, vascular targeting, improved PK/PD and vaccine will be briefly discussed. Highlighted Role of Nanobiotechnology and other enabling technologies in the followings: (1) Targeted drug delivery, (2) Improved PK and PD, (3) Early detection (Imaging), (4) Targeted delivery of chemotherapy for optimal efficacy and safety, (5) Nano synthesis and assembly of various platforms for targeted delivery and (6) Nanobiotechnology in shortening the time and risk of drug discovery and development.